Kymera Therapeutics Inc (NASDAQ:KYMR) price on Friday, February 07, fall -4.41% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $37.32.
A look at the stock’s price movement, the close in the last trading session was $39.04, moving within a range at $37.1875 and $39.4. The beta value (5-Year monthly) was 2.219. Turning to its 52-week performance, $53.27 and $29.24 were the 52-week high and 52-week low respectively. Overall, KYMR moved -8.80% over the past month.
Kymera Therapeutics Inc’s market cap currently stands at around $2.42 billion, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 14.81M for the company’s revenue for the quarter, with a low and high estimate of 2M and 65.7M respectively. The average forecast suggests down to a -69.06% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 53.83M, representing a -31.51% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that KYMR is a 100% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 3 analyst(s) rate the stock as a Hold, 5 recommend KYMR as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
KYMR’s current price about -7.83% and -11.03% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 39.16, while 7-day volatility ratio is 4.41% and 5.88% in the 30-day chart. Further, Kymera Therapeutics Inc (KYMR) has a beta value of 2.19, and an average true range (ATR) of 2.29. Analysts have given the company’s stock an average 52-week price target of $57, forecast between a low of $55 and high of $65. Looking at the price targets, the low is -47.37% off current price level while to achieve the yearly target high, price needs to move -74.17%. Nonetheless, investors will most likely welcome a -52.73% jump to $57 which is the analysts’ median price.
If we refocus on Kymera Therapeutics Inc (NASDAQ:KYMR), historical trading data shows that trading volumes averaged 0.47 over the past 10 days and 479.50K over the past 3 months. The company’s latest data on shares outstanding shows there are 64.75 million shares.
The 15.09% of Kymera Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 93.69% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 8.35 million on 2025-01-15, giving us a short ratio of 15.84. The data shows that as of 2025-01-15 short interest in Kymera Therapeutics Inc (KYMR) stood at 1439.9999999999998 of shares outstanding, with shares short falling to 8.79 million registered in 2024-12-13. Current price change has pushed the stock -7.23% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the KYMR stock continues to rise going into the next quarter.
